{"schema_version":"secwatch.filing_event.v1","accession":"0001688757-23-000014","form_type":"8-K","ticker":"ESTA","cik":"0001688757","company_name":"ESTABLISHMENT LABS HOLDINGS INC.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.147747+00:00","generated_at":"2026-06-18T23:46:47.874742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Establishment Labs submits final PMA module for Motiva to FDA; Q4 revenue $43.8M, up 24% YoY; guides 2023 $200-210M","bullets":["Submitted fourth and final module to U.S. FDA for premarket approval of Motiva Implants in the U.S.","Q4 2022 revenue $43.8M, up 24.1% YoY; operating loss $13.6M vs $14.2M loss in prior year.","2023 revenue guidance $200M-$210M, representing 24%-30% growth over 2022.","Cash balance $66.4M as of Dec 31, 2022; increased $12.9M from prior year.","Mia Femtech commercialization on track; China approval expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001688757-23-000014","json":"https://secwatch.observer/filing/0001688757-23-000014.json","markdown":"https://secwatch.observer/filing/0001688757-23-000014.md","text":"https://secwatch.observer/filing/0001688757-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1688757/000168875723000014/0001688757-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1688757/000168875723000014/esta-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:46:47.874742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68235acb381d4250be4504444b6eeb2c14e961bf","claim":"ESTABLISHMENT LABS HOLDINGS INC. reported the quarter ended December 31, 2022 results: revenue $43.8 million, net income $13.6 million. Guidance initiated.","evidence_excerpt":"Total revenue for the quarter ended December 31, 2022 was $43.8 million compared to $35.3 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1688757/000168875723000014/0001688757-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$43.8 million"},{"label":"Net income","value":"$13.6 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b52ec219a87a1a14d6553bcba553d6b4fc4f2de8","claim":"ESTABLISHMENT LABS HOLDINGS INC. updated its the year ended December 31, 2022 guidance (initiated).","evidence_excerpt":"The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022 and provided 2023 guidance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1688757/000168875723000014/0001688757-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}